Opinion|Videos|August 20, 2025
Adherence to Alopecia Areata Therapies
Key Takeaways
- Alopecia areata is a chronic autoimmune disorder causing non-scarring hair loss due to immune system attacks on hair follicles.
- Breakdown of immune privilege in hair follicles leads to infiltration by cytotoxic T cells, particularly CD8+ T cells.
Panelists discuss how adherence to conventional therapies for alopecia areata (AA) can be challenging, with adverse effects often impacting patient compliance, and how the most common cause of nonadherence is the lack of visible improvement or perceived efficacy.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Mostaghimi: How would you rate the overall adherence to conventional therapies in patients being treated for AA?
- Do the adverse effects of a patient's treatment typically affect adherence?
- What is the most common cause for nonadherence in patients with AA?
Advertisement
Related to this article
This analysis in RR MCL shows CAR T-cell therapy (brexucabtagene) yields higher complete responses vs bispecific antibodies; durability remains unclear.
Meta-analysis finds oral JAK inhibitors like baricitinib and ritlecitinib drive strong alopecia areata hair regrowth, improving SALT scores with manageable safety.
Follitropin delta yields cumulative ongoing pregnancy in 64.0% of patients under 35 and 43.9% of those 35 to 42 in 2 placebo-controlled IVF trials.
The Ambulatory Specialty Model aims to reduce chronic disease costs by mandating specialist participation and tying payments to quality and cost, while posing nationwide risk challenges.
Medicare drug price negotiations lowered out-of-pocket costs for some beneficiaries, but those reaching the annual Part D cap saw no direct savings.
AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.
Delphi consensus guides dermatology on spotting CTCL vs atopic dermatitis before/after dupilumab, using biopsy plus T-cell clonality testing and safer treatment switches.
Rosacea is likely missed, not rare, in skin of color, as low suspicion and hard-to-see redness delay diagnosis, said Hilary Baldwin, MD.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Drug Price Negotiations Yield Uneven Out-of-Pocket Savings
2
Lymphoma Outcomes Hinge on Oncology, Not Viral Load In People With HIV
3
Rusfertide Keeps Working Where Hydroxyurea Fades: Andrew Kuykendall, MD
4
New Mechanism of DME Treatment Highlights Clinical Trial Updates
5